FNWA
RXRX icon

Financial Network Wealth Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Financial Network Wealth Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$506 – 851
2025
Q2 		$506 Hold
100
– – ﹤0.01% 821
2025
Q1 		$529 Buy
+100
New +$729 ﹤0.01% 775
2024
Q4 		– Sell
-200
Closed -$1.32K – 779
2024
Q3 		$1.32K Hold
200
– – ﹤0.01% 712
2024
Q2 		$1.5K Buy
+200
New +$1.74K ﹤0.01% 776

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Financial Network Wealth Advisors's RXRX Position: Q3 2025 in Review

Financial Network Wealth Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 100 shares — an estimated $506 sold.

Financial Network Wealth Advisors first reported a position in RXRX in Q2 2024 and held it in 4 quarters. The position peaked at $1.5K in Q2 2024. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • Financial Network Wealth Advisors reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Financial Network Wealth Advisors sold 100 Recursion Pharmaceuticals shares in Q3 2025, an estimated $506.
  • Financial Network Wealth Advisors first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Financial Network Wealth Advisors's Recursion Pharmaceuticals position peaked at $1.5K in Q2 2024.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Financial Network Wealth Advisors's 13F filing for Q3 2025, filed 27 Oct 2025.